In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates
- PMID: 38880888
- PMCID: PMC11180387
- DOI: 10.1186/s40001-024-01885-6
In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are one of the most common causes of nosocomial infections and have high mortality rates due to difficulties in treatment. In this study, the in vitro synergistic interactions of the colistin (CT)-meropenem (MEM) combination and patient clinical outcomes were compared in CRAB-infected patients that receive CT-MEM antimicrobial combination therapy. In addition, in vitro synergistic interactions of MEM-ertapenem (ETP), MEM-fosfomycin (FF) and CT-FF antimicrobial combinations were investigated. Finally, the epsilometer (E) test and checkerboard test results were compared and the compatibility of these two tests was evaluated.
Methods: Twenty-one patients were included in the study. Bacterial identification was performed with MALDI-TOF, and antimicrobial susceptibility was assessed with an automated system. Synergy studies were performed using the E test and checkerboard method.
Results: For the checkerboard method, the synergy rates for CT-MEM, MEM-FF, MEM-ETP and CT-FF were 100%, 52.3%, 23.8% and 28.5%, respectively. In the E test synergy tests, synergistic effects were detected for two isolates each in the CT-MEM and CT-FF combinations. Microbial eradication was achieved in nine (52.9%) of the 17 patients that received CT-MEM combination therapy. The agreement between the E test and the checkerboard test was 6.5%.
Conclusions: A synergistic effect was found with the checkerboard method for the CT-MEM combination in all isolates in our study, and approximately 70% of the patients benefited from treatment with this combination. In addition, more than half of the isolates showed a synergistic effect for the MEM-FF combination. Combinations of CT-MEM and MEM-FF may be options for the treatment of CRAB infections. However, a comprehensive understanding of the potential of the microorganism to develop resistant mutants under applied exposures, as well as factors that directly affect antimicrobial activity, such as pharmacokinetics/pharmacodynamics, is essential for providing treatment advice. We found a low rate of agreement between the E test method and the checkerboard test method in our study, in contrast to the literature. Comprehensive studies that compare clinical results with methods are needed to determine the ideal synergy test and interpretation method.
Keywords: Carbapenem resistance Acinetobacter baumannii; Checkerboard assays; Combined antibiotic therapy; Epsilometer test synergy assays; In vitro antimicrobial interactions.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques.Front Cell Infect Microbiol. 2017 May 24;7:209. doi: 10.3389/fcimb.2017.00209. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28596943 Free PMC article.
-
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104. Mikrobiyol Bul. 2014. PMID: 24819268 Turkish.
-
Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.Antimicrob Agents Chemother. 2019 Mar 27;63(4):e01989-18. doi: 10.1128/AAC.01989-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745385 Free PMC article.
-
Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.Microb Drug Resist. 2017 Sep;23(6):744-756. doi: 10.1089/mdr.2016.0118. Epub 2017 Jan 13. Microb Drug Resist. 2017. PMID: 28085571
-
When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.Clin Lab Med. 2019 Sep;39(3):345-358. doi: 10.1016/j.cll.2019.04.002. Epub 2019 Jun 12. Clin Lab Med. 2019. PMID: 31383261 Free PMC article. Review.
Cited by
-
Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections.Pathogens. 2024 Nov 28;13(12):1049. doi: 10.3390/pathogens13121049. Pathogens. 2024. PMID: 39770308 Free PMC article. Review.
References
-
- Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–40. doi: 10.1016/S1473-3099(20)30796-9. - DOI - PubMed
-
- Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi: 10.1016/S1473-3099(18)30099-9. - DOI - PubMed
-
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. doi: 10.1093/cid/ciab1013. - DOI - PubMed
-
- Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine) Clin Microbiol Infect. 2022;28(4):521–547. doi: 10.1016/j.cmi.2021.11.025. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases